Ascelia Pharma

Ascelia Pharma Equity

The The Equity of Ascelia Pharma (ACE.ST) as of Oct 8, 2026 is 99.47 M SEK. In the previous year, The Equity was 78.94 M SEK — a change of 26.00% (higher).

Equity

99.47 MSEK

YoY

26.00%

Last updated:

In 2025, Ascelia Pharma's equity was 99.47 M SEK, a 26.00% increase from the 78.94 M SEK equity in the previous year.

The Ascelia Pharma Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
276.08 M SEK
Jan 1, 2019
237.06 M SEK
Jan 1, 2020
236.06 M SEK
Jan 1, 2021
307.83 M SEK
Jan 1, 2022
180.86 M SEK
Jan 1, 2023
74.33 M SEK
Jan 1, 2024
78.94 M SEK
Jan 1, 2025
99.47 M SEK
The Ascelia Pharma Equity history
YEAREquityYoY
99.47 MSEK+26.00%
78.94 MSEK+6.21%
74.33 MSEK-58.90%
180.86 MSEK-41.25%
307.83 MSEK+30.41%
236.06 MSEK-0.42%
237.06 MSEK-14.13%
276.08 MSEK+147.09%
111.73 MSEK+43.98%
77.60 MSEK—
Access this data via the Eulerpool API
Get Free API Key

Ascelia Pharma Stock analysis

What does Ascelia Pharma do? Ascelia Pharma is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Ascelia Pharma's Equity

Ascelia Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Ascelia Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Ascelia Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Ascelia Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Ascelia Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Ascelia Pharma stock

The Equity of Ascelia Pharma is 99.47 M SEK in 2025.

The Equity of Ascelia Pharma changed from 78.94 M SEK to 99.47 M SEK, representing a 26.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Ascelia Pharma since 2006 – with annual values, charts, and detailed analysis.

The Equity's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Ascelia Pharma historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Ascelia Pharma

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Ascelia Pharma